Remdesivir saves lives. Were 3 years needed to learn that?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providers.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026
   Article
2. Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
   Article

Corrections and comments

• Comment on
  Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.2023

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as